Search the GHTC website

Global health R&D delivers for New Hampshire

US government investment in global health R&D has delivered

$53.3 million
to New Hampshire research institutions
550+ new jobs
for New Hampshire
New Hampshire's top USG-funded global health R&D institutions

New Hampshire's top USG-funded global health R&D institutions

Dartmouth College (including Geisel School of Medicine)
$41.6 million
Celdara Medical LLC
$5.9 million
$1.7 million
University of New Hampshire
$1.6 million
Red River Technology
$647 thousand
$437 thousand

New Hampshire's top areas of global health R&D by USG funding

Bunyaviral diseases (including CCHF, RVF, SFTS)
Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Reproductive health
Arenaviral hemorrhagic fevers (including Lassa fever)
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Global health R&D at work in New Hampshire

A technology developed at the Geisel School of Medicine at Dartmouth was critical to the development of COVID-19 vaccines. In partnership with the US National Institutes of Health and other collaborators, in 2016, Dartmouth scientists figured out a method to stabilize the spike protein of coronaviruses so it could be used as an antigen—the immune-inducing element—in vaccines. This discovery was instrumental in enabling the rapid development of COVID-19 vaccines during the height of the COVID-19 pandemic. The technology was licensed to Moderna and BioNTech, the developers of the first-to-market vaccines used in the United States, as well as other vaccine companies, for use in creating their shots. Dartmouth now plans to reinvest the revenue generated from this technology into furthering other global health research.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: UNICEF for USAID/Fauzan Ijazah